Success Metrics

Clinical Success Rate
94.8%

Based on 73 completed trials

Completion Rate
95%(73/77)
Active Trials
0(0%)
Results Posted
7%(5 trials)
Terminated
4(5%)

Phase Distribution

Ph not_applicable
21
25%
Ph phase_2
27
32%
Ph phase_3
14
16%
Ph phase_1
20
24%
Ph phase_4
3
4%

Phase Distribution

20

Early Stage

27

Mid Stage

17

Late Stage

Phase Distribution85 total trials
Phase 1Safety & dosage
20(23.5%)
Phase 2Efficacy & side effects
27(31.8%)
Phase 3Large-scale testing
14(16.5%)
Phase 4Post-market surveillance
3(3.5%)
N/ANon-phased studies
21(24.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

93.6%

73 of 78 finished

Non-Completion Rate

6.4%

5 ended early

Currently Active

0

trials recruiting

Total Trials

85

all time

Status Distribution
Completed(73)
Terminated(5)
Other(7)

Detailed Status

Completed73
unknown5
Terminated4
Suspended2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
85
Active
0
Success Rate
94.8%
Most Advanced
Phase 4

Trials by Phase

Phase 120 (23.5%)
Phase 227 (31.8%)
Phase 314 (16.5%)
Phase 43 (3.5%)
N/A21 (24.7%)

Trials by Status

suspended22%
terminated45%
unknown56%
completed7386%
withdrawn11%

Recent Activity

Clinical Trials (85)

Showing 20 of 85 trialsScroll for more
NCT03077451Phase 2

Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma

Completed
NCT03829020Phase 1

Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Completed
NCT01959672Phase 2

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Completed
NCT01068327Phase 1

Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

Completed
NCT00003008Phase 2

Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed
NCT03050060Phase 2

Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer

Terminated
NCT00001091Phase 1

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed
NCT00000892Not Applicable

A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir

Completed
NCT00000872Phase 2

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Completed
NCT00001108Phase 1

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed
NCT00005762Not Applicable

Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

Completed
NCT00001087Phase 2

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed
NCT00017719Phase 3

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Completed
NCT00000912Phase 2

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients

Completed
NCT00000859Not Applicable

A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3

Completed
NCT00000899Phase 1

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Completed
NCT00000895Not Applicable

A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection

Completed
NCT00000914Not Applicable

A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

Completed
NCT00000924Phase 2

A Study to Compare Two Different Anti-HIV Drug Regimens

Completed
NCT00000893Phase 1

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Completed

Drug Details

Intervention Type
DRUG
Total Trials
85